Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (VERIFY)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Sponsor: Genzyme, a Sanofi Company
Listed as NCT01876784, this PHASE3 trial focuses on Differentiated Thyroid Cancer and remains completed. Sponsored by Genzyme, a Sanofi Company, it has been updated 16 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Dec 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Completed → Active Not Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Ann Arbor, United States , Barcelona, Spain , Barnaul, Russia , Beijing, China , Bordeaux, France , Boston, United States , Bunkyō City, Japan , Caen, France , Catania, Italy and 51 more locations